


Kindly amend the application as follows:

IN THE CLAIMS

Amend claims 12, 16-20 and 23 as follows*:

12. (Three Times Amended) A pharmaceutical composition comprising an N-acyl derivative of a D- or L-tryptophanyl-ester for the prophylaxis and/or therapy of oxidative pathologic processes in degenerative and/or cancer diseases having the following formula:



wherein X is C(O)R₁, and R₁ is a saturated C₁-C₁₈ hydrocarbon residue and R₂ is a saturated or unsaturated C₂-C₁₈ hydrocarbon residue, and a pharmaceutically acceptable carrier, alone or in combination with a second therapeutic compound.

C₂

16. (Amended) The pharmaceutical composition according to claim 12, wherein the N-acyl derivative is selected from the group consisting of N-acetyl-


* An Appendix of Amendments is attached herewith as Exhibit A showing the amendments. In the Appendix, deletions are indicated by brackets and additions are underlined.

C2
Cont

tryptophanoctyl-ester, N-acetyl-tryptophandodecyl-ester,
N-acetyl-tryptophanstearyl-ester, N-acetyl-
tryptophanpalmityl-ester, N-acetyl-tryptophanoleyl-ester,
N-dodecanoyl-tryptophanoctyl-ester, N-dodecanoyl-
tryptophandodecyl-ester, N-dodecanoyl-tryptophanstearyl-
ester, N-dodecanoyl-tryptophanpalmityl-ester, N-dodecanoyl-
tryptophanoleyl-ester, N-acetyl-tryptophanethyl-ester,
N-hexoyl-tryptophanethyl-ester, N-octoyl-tryptophanethyl-
ester, N-dodecanoyl-tryptophanethyl-ester, N-stearoyl-
tryptophanethyl-ester and N-palmitoyl-tryptophanethyl-ester.

17. (Amended) The pharmaceutical composition according to claim 12, wherein the N-acyl derivative, is an N-acetyl derivative and is selected from the group consisting of N-dodecanoyl-tryptophanethyl-ester.

18. (Amended) A pharmaceutical composition comprising an N-acyl derivative of a D- or L-tryptophanyl-ester, wherein the N-acyl derivative has the following formula:



wherein X is C(O)R₁, and R₁ is a saturated C₁-C₁₈ or unsaturated C₂-C₇ hydrocarbon residue and R₂ is a saturated or unsaturated C₉-C₁₈ hydrocarbon residue, and a pharmaceutically acceptable carrier.

19. (Amended) The pharmaceutical composition according to claim 18, wherein the N-acyl derivative is selected from the group consisting of N-acetyl-tryptophandodecyl-ester, N-acetyl-tryptophanstearyl-ester, N-acetyl-tryptophanpalmityl-ester, N-acetyl-tryptophanoleyl-ester, N-dodecanoyl-tryptophanoctyl-ester, N-dodecanoyl-tryptophandodecyl-ester, N-dodecanoyl-tryptophanstearyl-ester, N-dodecanoyl-tryptophanpalmityl-ester, N-dodecanoyl-tryptophanoleyl-ester, N-hexoyl-tryptophanethyl-ester, N-octoyl-tryptophanethyl-ester, N-dodecanoyl-tryptophanethyl-ester, N-stearoyl-tryptophanethyl-ester and N-palmitoyl-tryptophanethyl-ester.

20. (Amended) The pharmaceutical composition according to claim 18, wherein the N-acyl derivative is N-dodecanoyl-tryptophanethyl-ester.

23. (Amended) The pharmaceutical composition according to claim 12 or 21, wherein the second therapeutic compound is selected from the group consisting of ciliary neurotropic factor (CNTF), aniracetam, buflomedil, choline, co-dergocrine, cyclandelate, desferrioxamine, eptastigmine,

C3
Cont

fampridine, galantamine, isoxusuprine, lecithin,
linopiridine, metriphosphate, naftidrofuryl, nicergoline,
nicotine, nimodipine, oxiracetam, physostigmine,
pilocarpine, piracetam, pramiracetam, propentofylline,
pyritinol, RS-86, selegiline, suronacrine, tacrine,
velnacrine, somatomedines, protirelin, an immunoglobulin and
an immunosuppressive.

Please add claim 29 as follows:

C4

29. (Added) A pharmaceutical composition
comprising a D- or L-tryptophanyl-ester selected from the
group consisting of tryptophanoctyl-ester,
tryptophanstearyl-ester, tryptophanpalmityl-ester and
tryptophanoleyl-ester.
